Literature DB >> 21129101

Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis.

S N Anuj1, D M Whiley, T J Kidd, K A Ramsay, S C Bell, M W Syrmis, K Grimwood, C E Wainwright, M D Nissen, T P Sloots.   

Abstract

Pseudomonas aeruginosa genotyping relies mainly upon DNA fingerprinting methods, which can be subjective, expensive and time-consuming. The detection of at least three different clonal P. aeruginosa strains in patients attending two cystic fibrosis (CF) centres in a single Australian city prompted the design of a non-gel-based PCR method to enable clinical microbiology laboratories to readily identify these clonal strains. We designed a detection method utilizing heat-denatured P. aeruginosa isolates and a ten-single-nucleotide polymorphism (SNP) profile. Strain differences were detected by SYBR Green-based real-time PCR and high-resolution melting curve analysis (HRM10SNP assay). Overall, 106 P. aeruginosa sputum isolates collected from 74 patients with CF, as well as five reference strains, were analysed with the HRM10SNP assay, and the results were compared with those obtained by pulsed-field gel electrophoresis (PFGE). The HRM10SNP assay accurately identified all 45 isolates as members of one of the three major clonal strains characterized by PFGE in two Brisbane CF centres (Australian epidemic strain-1, Australian epidemic strain-2 and P42) from 61 other P. aeruginosa strains from Australian CF patients and two representative overseas epidemic strain isolates. The HRM10SNP method is simple, is relatively inexpensive and can be completed in <3 h. In our setting, it could be made easily available for clinical microbiology laboratories to screen for local P. aeruginosa strains and to guide infection control policies. Further studies are needed to determine whether the HRM10SNP assay can also be modified to detect additional clonal strains that are prevalent in other CF centres.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21129101     DOI: 10.1111/j.1469-0691.2010.03439.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

Review 1.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

2.  A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Melanie W Syrmis; Timothy J Kidd; Ralf J Moser; Kay A Ramsay; Kristen M Gibson; Snehal Anuj; Scott C Bell; Claire E Wainwright; Keith Grimwood; Michael Nissen; Theo P Sloots; David M Whiley
Journal:  BMC Infect Dis       Date:  2014-06-05       Impact factor: 3.090

3.  Detection of algD, oprL and exoA Genes by New Specific Primers as an Efficient, Rapid and Accurate Procedure for Direct Diagnosis of Pseudomonas aeruginosa Strains in Clinical Samples.

Authors:  Sedighe Rashno Taee; Behzad Khansarinejad; Hamid Abtahi; Mohammad Najafimosleh; Ehsanollah Ghaznavi-Rad
Journal:  Jundishapur J Microbiol       Date:  2014-10-01       Impact factor: 0.747

4.  Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Authors:  Anna S Tai; Laura J Sherrard; Timothy J Kidd; Kay A Ramsay; Cameron Buckley; Melanie Syrmis; Keith Grimwood; Scott C Bell; David M Whiley
Journal:  BMC Pulm Med       Date:  2017-11-02       Impact factor: 3.317

5.  SNaPaer: a practical single nucleotide polymorphism multiplex assay for genotyping of Pseudomonas aeruginosa.

Authors:  Nadia Eusebio; Tiago Pinheiro; Adelina A Amorim; Fernanda Gamboa; Lucília Saraiva; Leonor Gusmão; António Amorim; Ricardo Araujo
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.